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The hereditary spastic ataxias (HSA) are a group of clinically heterogeneous neurodegenerative disorders characterized
by lower-limb spasticity and generalized ataxia. HSA was diagnosed in three unrelated autosomal dominant families
from Newfoundland, who presented mainly with severe leg spasticity, dysarthria, dysphagia, and ocular-movement
abnormalities. A genomewide scan was performed on one family, and linkage to a novel locus for HSA on chromosome
12p13, which contains the as-yet-unidentified gene locus SAX1, was identified. Fine mapping confirmed linkage in
the two large families, and the third, smaller family showed LOD scores suggestive of linkage. Haplotype construction
by use of 13 polymorphic markers revealed that all three families share a disease haplotype, which key recombinants
and overlapping haplotypes refine to ∼5 cM, flanked by markers D12S93 and GATA151H05. SAX1 is the first locus
mapped for autosomal dominant HSA.
Hereditary spastic ataxia (HSA) comprises a heteroge-
neous group of progressive neurodegenerative disorders
characterized by lower-limb spasticity and generalized
ataxia with dysarthria, with impaired ocular movements,
and with gait disturbance (Mahloudji 1963; Bouchard et
al. 2000). HSA presents as dominant (MIM 108600) and
recessive (MIM 270500) types, the latter of which in-
cludes autosomal recessive spastic ataxia of Charlevoix-
Saguenay (ARSACS [MIM 270550]) (De Braekeleer et al.
1993). The disease gene causing ARSACS has been iden-
tified on chromosome 13q11 (MIM 604490) and encodes
sacsin, a protein that is thought to be involved in chap-
erone-mediated protein folding (Engert et al. 2000).
Three large families (13, 27, and 71) with autosomal
dominant HSA were identified in Newfoundland (Gre-
wal et al. 2001) and independently assessed, mostly by
a single neurologist (M.S.), by use of a standard pro-
tocol. The majority of affected individuals initially pre-
sent with progressive leg spasticity of variable degrees
followed by ataxia in the form of involuntary head jerk,
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dysarthria, dysphagia, and ocular-movement abnormal-
ities with no signs of amyotrophy. The lower limbs show
hyperreflexia and hypertonicity. The ocular-movement
abnormalities include slow saccades, impaired vertical
gaze, and, in some cases, lid retraction. A few patients
have additional features, such as dystonia, pes cavus,
mild ptosis, and decreased vibration sense in lower limbs.
This phenotype resembles that observed in ARSACS;
however, these three families are from a different pop-
ulation and show a clear pattern of dominant inheritance
with a later age at onset than is seen in ARSACS (Bou-
chard et al. 2000).
The severity of the phenotype in the three families
varies greatly within and among the families, and the
age at onset is from early childhood to early 20s, al-
though the majority of patients start presenting with
symptoms at age 10–20 years. The available neuro-
pathological data indicate degeneration of the cortico-
spinal tracts and posterior columns. The life span and
cognition of patients is not affected, and there is no
obvious kinship between these three families (Grewal et
al. 2001; K.K.G., unpublished data).
Twenty-nine individuals have been collected from
family 71, of whom 14 are clinically affected and 15 are
unaffected (fig. 1). The largest family is family 13, from
which 50 individuals have been collected: 21 affected
and 29 unaffected (fig. 2). Finally, family 27 is a small
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Figure 1 Informative section of family 71, with the chromosome 12p13 haplotype. The disease haplotype for HSA is indicated by the blackened bar. Affected individuals are indicated by blackened
symbols, unaffected individuals are indicated by unblackened symbols, and key recombinants (VI:4 and VI:13) are indicated by an asterisk (*). These recombinants determined the critical interval to be
10 cM, flanked by markers D12S1685 and GATA151H05.
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Figure 2 Informative section of family 13, with the chromosome 12p13 haplotype. The disease haplotype for HSA is indicated by the blackened bar. Affected individuals are indicated by
blackened symbols, unaffected individuals are indicated by unblackened symbols, key recombinants (V:14 and VI:11) are indicated by an asterisk (*), and possibly affected individuals are indicated
by a question mark (?). These recombinants determined the critical region to be 8 cM, flanked by markers D12S1725 and D12S397.
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Figure 3 Informative section of family 27, with the chromosome 12p13 haplotype. The disease haplotype for HSA is indicated by the
blackened bar. Affected individuals are indicated by blackened symbols, and unaffected individuals are indicated by unblackened symbols.
Individual III:4 shares the complete haplotype and is unaffected.
collection of seven individuals, of whom three are af-
fected (fig. 3). Blood was collected from consenting fam-
ily members, age 19 years, and DNA was extracted
using a salting-out method (Miller et al. 1988).
To map the gene causing HSA in these three dominant
kindreds, a genomewide scan of the 22 autosomes was
performed on family 71. Although this family is not the
largest pedigree, the individuals in it are more closely
related, and fewer individuals were required for signif-
icant linkage results. Approximately 400 evenly spaced
polymorphic microsatellite markers throughout the ge-
nome were used. Two-point parametric linkage analysis
was performed for each marker by use of the FASTLINK
(version 4.1) software package. The parameters in the
linkage analysis were (a) an estimated disease gene fre-
quency of 1/10,000, (b) a penetrance of 90%, (c) equal
male and female recombination frequencies, and (d) Cen-
tre d’E´tude du Polymorphisme Humain (CEPH) marker-
allele frequencies. Additional polymorphic markers were
genotyped to further investigate the positive linkage re-
sults. These markers and their order were obtained from
the Marshfield genetic map (Center for Medical Genet-
ics, Marshfield Medical Research Foundation), and the
primer sequences were obtained from the Genome Da-
tabase and the Cooperative Human Linkage Center da-
tabase. These polymorphic markers were amplified by
PCR, which incorporated a radiolabeled nucleotide (S35-
dATP ) in the product. The PCR products were separated
on 6% denaturing polyacrylamide gels and detected by
exposure to autoradiographic film. The alleles were as-
signed on the basis of their size, with comparison to a
M13mp18 sequence ladder. The MLINK program of the
FASTLINK software package was then used to perform
two-point parametric linkage analysis on the genotype
data (Cottingham et al. 1993). Haplotypes of individuals
with inferred genotypes were constructed under the as-
sumption of minimal recombination.
Linkage analysis of the genomewide-scan data iden-
tified linkage of family 71 to marker D12S374 on chro-
mosome 12, with a LOD score slightly greater than 3
at ; no other LOD scores greater than 2 werevp 0
found. Following the genome scan, seven additional
markers over an 11-cM interval were genotyped, and
the results confirmed linkage to a novel locus for HSA
on chromosome 12p13 (table 1). The highest LOD score
was obtained for markers D12S374 (4.8 at ) andvp 0
D12S93 (5.1 at ). The locus for dentatorubral pal-vp 0
lidoluysian atrophy (DRPLA) (MIM 125370) is in the
vicinity of marker D12S374, but two individuals from
each of the three families tested negative for expansions
in the DRPLA gene (G.A.R., unpublished data).
Once linkage of family 71 was confirmed, all markers
were also tested in families 13 and 27. Family 13 showed
highly significant linkage to the new locus, with a highest
LOD score, 7.2, at for markers D12S93 andvp 0
D12S374 both, which are 1.6 cM apart (table 2). The
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Table 1
LOD Scores for Chromosome 12 in Family 71
MARKER
POSITION
(cM)
LOD SCORE AT v p
0 .01 .05 .1 .2 .3 .4
D12S1725 9.52 .909 1.007 1.190 1.223 1.031 .667 .241
D12S314 11.37 1.439 1.450 1.455 1.401 1.174 .846 .420
D12S93 12.60 5.092 5.026 4.729 4.294 3.265 2.057 .766
D12S374 14.23 4.884 4.819 4.521 4.085 3.057 1.852 .575
D12S1623 15.69 1.248 1.056 .676 .450 .229 .118 .051
D12S397 17.72 4.083 .903 1.834 2.070 1.820 1.178 .396
D12S1695 19.68 1.447 1.704 2.429 2.535 2.119 1.322 .373
D12S77 20.27 1.773 2.314 2.920 2.907 2.316 1.397 .371
Table 2
LOD Scores for Chromosome 12 in Family 13
MARKER
POSITION
(cM)
LOD SCORE AT v p
0 .01 .05 .1 .2 .3 .4
D12S1725 9.52 2.904 6.058 6.180 5.691 4.241 2.527 .882
D12S314 11.37 2.461 5.086 5.997 5.9142 4.948 3.500 1.776
D12S93 12.60 7.293 7.142 6.526 5.736 4.104 2.447 .905
D12S374 14.23 7.223 7.324 7.325 6.9685 5.749 4.106 2.135
D12S1623 15.69 1.107 1.265 1.489 1.545 1.374 .981 .458
D12S397 17.72 4.342 1.562 2.398 2.384 2.261 1.553 .713
D12S1695 19.68 2.487 6.808 7.204 6.932 5.719 4.028 2.017
D12S77 20.27 .679 5.291 5.948 5.918 5.071 3.678 1.917
highest LOD score for family 27 was 0.45 at forvp 0
marker D12S1623. The SLINK program of the LINK-
AGE software program was used to simulate linkage in
family 27, and the highest LOD score attainable was
predicted to be 1.18 at . Interestingly, none ofvp 0.01
the markers showed a negative LOD score, and, given
the small number of samples, these results indicate sug-
gestive linkage of this family to the new locus (table 3).
A disease haplotype was established for each family.
In family 71, key recombinants (VI:4 and VI:13) deter-
mined the smallest critical interval to be 10 cM, flanked
by markers D12S1685 and GATA151H05. The haplo-
type was constructed by following the order of markers
available from the Human Genome Project Working
Draft database. Haplotype analysis for the same critical
markers in families 13 and 27 identified an identical
disease haplotype over an 11-marker interval for both
families. It is highly unlikely that two families share the
same alleles over an 11-marker interval by chance. For
family 13, the key recombinants V:14 and VI:11 deter-
mined the critical interval to be 8 cM, flanked by mark-
ers D12S1725 and D12S397.
When the disease haplotypes of the three families are
overlapped, the smallest common disease haplotype is
5.1 cM, flanked by markers D12S93 and GATA151H05
(table 4). This interval contains the as-yet-unidentified
disease gene, which has been assigned the symbol SAX1
by the HUGO Gene Nomenclature Committee. All af-
fected individuals in each family inherited this identical
segment of DNA. The shared haplotype in the three
Newfoundland families suggests that they originate from
a common ancestor in Newfoundland. It therefore is
likely that a common mutation will be identified for
these three families, which would facilitate a genetic-
testing program in Newfoundland. However, there is
currently no genealogical evidence that these families are
related, and available family records will be further stud-
ied in search of a common ancestor. Furthermore, there
are a few individuals (individuals VI:14 and VI:15 in
family 13 and individual III:4 in family 27) who are
presently unaffected but share part of or the entire 5.1-
cM region. These individuals may be presymptomatic
or asymptomatic, which can be explained by age-de-
pendent or reduced penetrance of HSA.
According to the Human Genome Project Working
Draft sequence, the smallest disease haplotype, 5.1 cM,
corresponds to ∼3.7 Mb on the physical map and con-
tains three large unsequenced gaps. There are 40 known
genes and 52 predicted genes in this interval. Additional
polymorphic dinucleotide repeats can be identified using
the Human Genome Project Working Draft database.
Furthermore, single-nucleotide polymorphisms in the
known genes can also be used to further refine the dis-
ease haplotype. Finally, the collection of affected family
members—for family 27 in particular and possibly for
new families—will continue, in an effort to identify more
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Table 3
LOD Scores for Chromosome 12 in Family 27
MARKER
POSITION
(cM)
LOD SCORE AT v p
0 .01 .05 .1 .2 .3 .4
D12S1725 9.52 .226 .241 .273 .276 .217 .123 .037
D12S314 11.37 .355 .367 .391 .380 .285 .154 .042
D12S93 12.60 .280 .271 .238 .197 .122 .059 .016
D12S374 14.23 .354 .367 .389 .378 .281 .148 .039
D12S1623 15.69 .448 .437 .391 .333 .217 .110 .030
D12S397 17.72 .259 .273 .303 .301 .230 .126 .036
D12S1695 19.68 .333 .346 .370 .359 .266 .137 .035
D12S77 20.27 .349 .362 .386 .374 .279 .148 .039
Table 4
SAX1 Locus on Chromosome 12p13 Determined by Key
Recombinants and Overlapping of Haplotypes
MARKER
FAMILYa
MINIMAL
COMMONLY
INHERITED
SEGMENT
[SIZE]b71 13 27
D12S1685 13 6 6
D12S1725 1 6 6
D12S314 5 8 8
D12S93 7 1 1
D12S374c 5 5 5 5 [209 bp]
D12S1623 4 4 4 4 [127 bp]
DRPLA 2 2 2 2 [180 bp]
GATA151H05 5 5 5
D12S397 3 3 3
D12S1695 6 6 6
D12S77 4 4 4
D12S89c 8 8 …
D12S391 5 4 …
a The boxed regions in these columns indicate the minimal disease
interval determined by key recombinants. Note that there were no key
recombinants identified for family 27 in this interval.
b The boxed region in this column represents theminimal commonly
inherited disease haplotype of 5.1 cM, which was obtained by over-
lapping the critical disease intervals of each family. To standardize the
results, the size of the marker alleles is provided.
c All three families share part of their haplotypes from D12S374 to
D21S89.
recombinations to further narrow the region.Meanwhile,
interesting candidate genes will be screened, with priority
placed on expression profiles and possiblemolecular func-
tion in disease pathogenesis.
HSA is clinically related to the hereditary spastic par-
aplegias (HSPs) and the spinocerebellar ataxias (SCAs)
(Bouchard et al. 2000; Tallaksen et al. 2001). Lower-
limb spasticity is marked in HSA but is also the hallmark
of HSP. The main pathological feature is axonal degen-
eration of the terminal ends of the corticospinal tracts
and the dorsal-column–pathway tracts (McDermott et
al. 2000). At present, the defective proteins implicated
in HSP pathogenesis are the L1 cell-adhesion molecule
(L1CAM), which is involved in the development of the
nervous system; the proteolipid protein (PLP), which is
involved in myelin-sheet compaction and maintenance;
and two AAA (ATPase with various cellular activities)
family members, paraplegin and spastin. Paraplegin is a
mitochondrial metalloprotease, and spastin is thought to
act as a chaperone (Casari and Rugarli 2001). Recently,
HSP-causing mutations have also been identified in a
GTPase gene, which encodes atlastin, a protein thought
to be involved in vesicle trafficking (Zhao et al. 2001).
SCAs are another group of clinically heterogeneous
neurodegenerative disorders. This group is characterized
by degeneration of the cerebellum, brain stem, and spinal
cord (Harding 1993). Evidence suggests that trinucleo-
tide-repeat expansions are the main pathogenic mecha-
nism for autosomal dominant cerebellar ataxias, includ-
ing DRPLA and Machado-Joseph disease (Nakamura et
al. 2001; Tan and Ashizawa 2001), although the under-
lying cause of the cell degeneration observed remains un-
known (Klockgether et al. 2000).
Genes homologous to any of the known HSP, SCA,
or ARSACS genes; AAA family members; L1CAM; PLP;
GTPases; and sacsin present in the 3.7-Mb interval will
be investigated. Interestingly, DRPLA cannot be ex-
cluded as a candidate gene and will be considered for
point-mutation screening. Anticipation has not been ob-
served in any of the three families, which suggests that
a DNA-repeat expansion is less likely to be responsible
for SAX1. Other interesting candidates in the region are
vesicle-associated–membrane protein 1 (VAMP1), a syn-
aptobrevin involved in vesicle transport to the synapse
(Archer et al. 1990), and g-enolase (ENO2), a neuron-
specific enzyme with increased expression during cell
death (Craig et al. 1990; Lafon-Cazal et al. 1992).
In an effort to find the molecular cause of a pheno-
typically distinct clinical disorder (HSA), we identified
the first locus for dominant HSA on chromosome 12p13.
This suggests that, in HSA, there is locus heterogeneity
with two identified loci—SAX1 and ARSACS. Pin-
pointing the disease gene would facilitate clinical di-
agnosis, which is often difficult in HSA. In addition, a
genetic-testing program and improved clinical diag-
nosis in Newfoundland would be feasible with the ev-
idence of a common ancestor. The characterization of
the disease-causing gene and defective protein will pro-
vide more insight into the disease pathogenesis of this
and other related neurodegenerative diseases, such as
HSP, SCA, and amyotrophic lateral sclerosis.
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